This expanded BOTOX ® dosing guidance provides physicians the ability to treat based on clinical assessment of a patient's spasticity and anatomy while staying within the BOTOX ® maximum cumulative dose of 400 Units in a 3-month period in adults. This can result in difficulty with posture and positioning, and severely interfere with normal muscular movement and function.īOTOX ® has been proven to significantly reduce muscle stiffness and is indicated for the treatment of spasticity in patients 2 years of age and older. Upper limb spasticity can manifest as a bent elbow, an arm pressed against the chest, or a curled-in hand with a clenched fist, significantly hindering the patient's ability to perform everyday activities. Individuals with spasticity experience stiffness in the muscles of their upper and/or lower limbs, and may have difficulty with voluntary control.
Spasticity in adults is commonly caused by stroke, multiple sclerosis, spinal cord injury, cerebral palsy, and traumatic brain injury. BOTOX ® provides an evidence-based dosing strategy to meet the clinical needs of providers and their patients." Brin, M.D., Senior Vice President, Chief Scientific Officer, BOTOX ® & Neurotoxins, AbbVie. "This label expansion not only adds to our rich history in neurotoxin science, but also reinforces the role of BOTOX ® in upper limb spasticity treatment.
"Today's announcement is especially important because spasticity is a disabling neurological condition that can have a significant impact on a patient's quality of life," said Mitchell F. The label now includes the use of ultrasound as a muscle localization technique in adult spasticity. Food and Drug Administration (FDA) has approved a label expansion of BOTOX ® to include eight new muscles for the treatment of upper limb spasticity in adults. The new muscles for treatment include additional muscles of the elbow and forearm (brachialis, brachioradialis, pronator teres, and pronator quadratus), as well as intrinsic hand muscles (lumbricals and interossei) and thumb muscles (flexor pollicis brevis and opponens pollicis). NORTH CHICAGO, Ill., J/PRNewswire/ - Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S.
0 kommentar(er)
